Nuvelo Starts Phase II Trial Of Alfimeprase In Ischemic Stroke
This article was originally published in Pharmaceutical Approvals Monthly
Nuvelo has begun a Phase II trial for alfimeprase as a therapy for ischemic stroke patients during hours three through nine following onset of symptoms, the company announced Dec. 12.
You may also be interested in...
US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.